loader
Please Wait
Applying Filters...

Annual Sales of Trametinib reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies.

Menu
$ API Ref.Price (USD/KG) : 528,950Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 1Mekinist

02 5Tafinlar/Mekinist

PharmaCompass

01

Brand Name : Tafinlar/Mekinist

Trametinib

arrow
Luxepack
Not Confirmed

Brand Name : Tafinlar/Mekinist

arrow
Luxepack
Not Confirmed

Trametinib

Main Therapeutic Indication : Oncology

Currency : USD

2020 Revenue in Millions : 1,542

2019 Revenue in Millions : 1,338

Growth (%) : 15

blank

02

Brand Name : Tafinlar/Mekinist

Trametinib

arrow
Luxepack
Not Confirmed

Brand Name : Tafinlar/Mekinist

arrow
Luxepack
Not Confirmed

Trametinib

Main Therapeutic Indication : Oncology

Currency : USD

2021 Revenue in Millions : 1,693

2020 Revenue in Millions : 1,542

Growth (%) : 10

blank

03

Brand Name : Tafinlar/Mekinist

Trametinib

arrow
Luxepack
Not Confirmed

Brand Name : Tafinlar/Mekinist

arrow
Luxepack
Not Confirmed

Trametinib

Main Therapeutic Indication : Oncology

Currency : USD

2022 Revenue in Millions : 1,770

2021 Revenue in Millions : 1,693

Growth (%) : 5

blank

04

Brand Name : Tafinlar/Mekinist

Trametinib

arrow
Luxepack
Not Confirmed

Brand Name : Tafinlar/Mekinist

arrow
Luxepack
Not Confirmed

Trametinib

Main Therapeutic Indication : Oncology

Currency : USD

2023 Revenue in Millions : 1,922

2022 Revenue in Millions : 1,770

Growth (%) : 9

blank

05

Brand Name : Mekinist

Trametinib

arrow
Luxepack
Not Confirmed

06

Brand Name : Tafinlar/Mekinist

Trametinib

arrow
Luxepack
Not Confirmed

Brand Name : Tafinlar/Mekinist

arrow
Luxepack
Not Confirmed

Trametinib

Main Therapeutic Indication : Oncology

Currency : USD

2019 Revenue in Millions : 1,338

2018 Revenue in Millions : 1,155

Growth (%) : 16

blank